The U.S. Food and Drug Administration has approved Indianapolis-based Eli Lilly's new treatment for moderate to severe eczema ...

In a lawsuit, the FTC accused Optum Rx, Caremark and Express Scripts of creating "a broken rebate system that inflated ...

Eli Lilly's long-term growth prospects are strong with improved supply, new growth opportunities, and competitive positioning ...

Although Lilly started consistently raising its dividend in 2015, investors should be aware of some details around the schedule of these payments. Every year since then, Lilly announced a hike to its ...

In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Buy rating on Eli Lilly & Co (LLY – ...

Wells Fargo analyst Mohit Bansal assigned a Buy rating on Eli Lilly & Co (LLY – Research Report) yesterday and set a price target of ...

Eli Lilly surged 58% in 2024, driven by weight-loss drugs and strong earnings. The technical chart shows consolidation. See ...

Morgan Stanley laid out a to-do list for Google's new finance chief. Here's what they want.

Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental ...

Today, the Lonza Board of Directors announced the nomination of Juan Andres and Eric Drapé as Independent Members of the Board. The Board will propose to shareholders the election of both nominees at ...

For significant weight loss, Zepbound may be the better option. If you have Type 2 diabetes and are looking for a dual ...

Aegis Life, Inc. (Aegis) and its partner Entos® Pharmaceuticals (Entos), announced today that the Phase 1 portion of a Phase ...